You searched for "therapeutics"
Birdshot retinochoroiditis
Birdshot retinochoroiditis (BRC) is a chronic, sight-threatening uveitis, most commonly affecting caucasian individuals in their fourth to sixth decades [1]. The disease is associated with HLA-29 and is characterised by progressive inflammation at the level of retina and choroid, with...Pegcetacoplan: A breakthrough treatment for dry age-related macular degeneration?
Age-related macular degeneration (AMD) is a degenerative condition affecting the macula, the part of the retina responsible for central vision. It is characterised by the presence of drusen and retinal pigment epithelium (RPE) abnormalities in the absence of other macular...The role of aspirin in the treatment of NAION: Benefits and controversies
4 December 2024
| Ali Yagan
|
EYE - Neuro-ophthalmology
Non-arteritic anterior ischaemic optic neuropathy (NAION) is the most common acute optic neuropathy in individuals over 50 with estimated prevalence of 2–10 per 100,000 people, characterised by sudden, unilateral vision loss due to ischaemic injury to the optic nerve head....
Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions
1 August 2018
| Rod McNeil
|
EYE - General
Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...
Conservative management of concomitant strabismus
1 October 2019
| Joe Smith
|
EYE - General
The aim of management for all patients with strabismus should centre around four goals: to prevent amblyopia, to alleviate symptoms, to restore binocular single vision (BSV) and to improve ocular alignment. The conservative management options available for strabismus include observation,...
An update on idiopathic intracranial hypertension
1 August 2017
| Susan P Mollan, Alex Sinclair
|
EYE - Neuro-ophthalmology
The incidence of Idiopathic intracranial hypertension (IIH) is increasing, likely in line with the worldwide epidemic of obesity. To date, there have been revisions in the terminology used and diagnostic criteria for IIH; these recognise the need to exclude secondary...
Eye research: where next?
1 December 2017
| Rod McNeil
|
EYE - General
Eye research in the UK is underfunded relative to other areas of medical research and general awareness of sight loss and its prevention remains poor, messages that were reinforced in presentations and discussions during a recent research summit meeting in...
My top five: Innovative approaches to dry AMD
2 February 2024
| Nikhil Sharma
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...
My Top Five: Innovative approaches to dry AMD
2 February 2024
| Nikhil Sharma
|
EYE - General
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...
Refined glaucoma referral practice offers prospect of improved capacity and expanded role for primary eye care professionals
1 February 2018
| Rod McNeil
|
EYE - Glaucoma
Glaucoma is the most frequent cause of irreversible blindness worldwide and the second leading cause of blindness in the UK [1,2]. The global prevalence of glaucoma in 2010 was approximately 3.5% for people aged 40-80 years, according to Jonas et...
Age and gender impacts effectiveness of new gene therapy treatments for eye diseases, new study finds
14 February 2025
|
research, genetics, gene therapy, pathology, education, Adeno-Associated Virus, inflammation
Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found. The University of Bristol-led study, published in Molecular Therapy, reveal how age and gender affects inflammation caused by gene...
Andy Hill (NuVision Biotherapies) discusses recent AOP update to clinical guidelines
8 December 2023
|
NuVision, Andy Hill, amniotic membranes, guidelines, AOP, optometrist, outpatient, dry eye, lens
There are currently 600,000 people on the NHS waiting list for ophthalmology treatment, and over 5 million people in the UK currently live with dry eye disease. Here Andy Hill, CEO at NuVision Biotherapies Ltd, discusses a recent update to clinical guidelines and what this means for optometrists, patients, and taxpayers.
